The link between the modification of BCL2’s chromatin architecture and its constitutive activation in estrogen-resistant cancer cells has been demonstrated, identifying JMJD3 and methyltransferase EZH2 as interesting therapeutic targets. This evidence concerns the gene BCL2 and cancer.